drugset / Trial / NCT03950570
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates the anti-tumor effects of ORIN 1001 in patients with advanced solid tumors or relapsed refractory metastatic breast cancer (patients with progressive disease after receiving at least two lines of therapy in the advanced setting).
Timeline
- Start
- 2019-05-25
- Primary completion
- 2023-01-30
- Completion
- 2023-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORIN1001 | Unknown | — | Oral |
| Background | Abraxane | Small molecule | — | Intravenous |